Quality of Life among Hepatocellular Carcinoma Patients Received Transcatheter Arterial Chemoembolization: Longitudinal Prospective Study
Article Sidebar
Main Article Content
Abstract
The quality of life among hepatocellular carcinoma patients received with TACE each period is different, with various factors involved both internally and externally. This descriptive research aimed to compare the quality of life among hepatocellular carcinoma patients received TACE ≤ 3 times and ≥ 4 times. Data were collected at a university hospital in southern Thailand, from November 2017 to June 2019. Sixty-five hepatocellular carcinoma patients were recruited and received TACE 293 times, collecting data continuously for 6 times, before receiving initial TACE and after receiving TACE 1-5 times. Research instruments included the EORTC QLQ-C30 and HCC18. Cronbach’s alphas for the EORTC QLQ-C30 and HCC18 questionnaires were 0.79 and 0.80, respectively. Data were analyzed using paired t-test. Results show that: (1) The level of global health status of hepatocellular carcinoma patients received with TACE ≤ 3 times, ≥ 4 times were good and higher than initial receiving TACE. (2) There was no significant mean score global health status of hepatocellular carcinoma patients who received with TACE ≤ 3 times, ≥ 4 times. The results showed that TACE treatment for hepatocellular carcinoma patients can improve quality of life.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Zhong JH, Peng NF, You XM, Ma L, Xiang X, Wang YY, et al. Tumor stage and primary treatment of hepatocellular carcinoma at a large tertiary hospital in China: A real-world study. Oncotarget 2017; 8(11): 18296-302.
Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019; 72: 28-36.
Song DS, Nam SW, Bae SH, Kim JD, Jang JW, Song MJ, et al. Outcome of transarterial chemoembolization-based multi-modal treatment in patients with unresectable hepatocellular carcinoma. World J Gastroenterol 2015 ;21(8): 2395-404.
Kaewdech A, Sripongpun P, Cheewasereechon N, Jandee S, Chamroonkul N, Piratvisuth T. Validation of the "Six-and-Twelve" prognostic score in transarterial chemoembolization-treated hepatocellular carcinoma patients. Clin Transl Gastroenterol 2021; 12(2): e00310.
Lee JS, Kim BK, Kim SU, Park JY, Ahn SH, Seong JS, et al. A survey on transarterial chemoembolization refractoriness and a real-world treatment pattern for hepatocellular carcinoma in Korea. Clin Mol Hepatol 2020; 26(1): 24-32.
Marcacuzco Quinto A, Nutu OA, San Román Manso R, Justo Alonso I, Calvo Pulido J, Manrique Municio A, et al. Complications of transarterial chemoembolization (TACE) in the treatment of liver tumors. Cir Esp (Engl Ed). 2018; 96(9): 560-67.
Peplau HE. Quality of life: An interpersonal perspective. Nurs Sci Q 1994; 7(1): 10-5.
Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg 2016; 2016: 6120143. doi: 10.1155/2016/6120143.
Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol 2015; 30(7): 1167-74.
Nillert A., Srimoragot P., Wongkongkam K., Thamtorawat S. Factors predicting quality of life of hepatocellular carcinoma patients undergoing tranarterial chemoemolization. Thai J Nursing Council 2019; 34(2): 127-40.
Temthup S. Indicator report of advanced nurse practitioner, Nursing Services Division, Songklanagarind Hospital; 2017. (In Thai)
Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Sirachainan E, Ratanatharathorn V. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version. Qual Life Res 2006; 15(1): 167-72.
Temthup S, Nilmanut k, Udomvisatson R, Hongsakul K. Quality of life among hepatocellular carcinoma patients who receive initial transcatheter arterial chemoembolization. J Public Healt Nurs 2020; 34(1): 63-79. (In Thai)
Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, Ye Z. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer 2013; 21(2): 475-83.
Polit DF, Beck CT. Nursing research: generating and assessing evidence for nursing practice. 8thed.
Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-55.
Hartrumpf KJ, Marquardt S, Werncke T, Murray T, Kirstein MM, Vogel A, et al. Quality of life in patients undergoing repetitive TACE for the treatment of intermediate stage HCC. J Cancer Res Clin Oncol 2018; 144(10): 1991-9.
Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, et al. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol 2015; 30(7): 1167-74.
Shun SC, Chou YJ, Chen CH, Yang JC. Change of uncertainty in illness and unmet care needs in patients with recurrent hepatocellular carcinoma during active treatment. Cancer Nurs 2018; 41(4): 279-89.
Wang ZX, Yuan CQ, Guan J, Liu SL, Sun CH, Kim SH. Factors associated with psychological characteristic patients with hepatic malignancy before intervention procedures. Asian Pacific J Cancer Prev 2012; 13:309-14.
Paul C, Boyes A, Hall A, Bisquera A, Miller A, O'Brien L. The impact of cancer diagnosis and treatment on employment, income, treatment